PharmaShots | Incisive News in 3 Shots

Subscribe Now

Exercised

Boehringer Ingelheim Exercised its Option to License Oxford Biomedica's Lentiviral Vector Technology to Commercialize BI 3720931 for CF

Boehringer Ingelheim Exercised its Option to License Oxford Biomedica's Lentiviral Vector Technology to Commercialize BI 3720931 f...

October 20, 2021

Pfizer Exercised its Option to License AnTolRx's Immune Tolerance Therapy for Type 1 Diabetes (T1D)

Pfizer Exercised its Option to License AnTolRx's Immune Tolerance Therapy for Type 1 Diabetes (T1D)

March 6, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us